For cardiologists and patients navigating mitral valve disease alongside kidney failure, a fundamental assumption is being challenged: the hemodynamic benchmarks used to define procedural success may carry far less prognostic weight in people on chronic dialysis than in the general cardiac population. This distinction has direct implications for how outcomes are interpreted and how post-procedural management is structured.
Drawing from the prospective, multicenter OCEAN-Mitral registry — one of the largest real-world datasets for transcatheter edge-to-edge mitral repair (TEER) — investigators analyzed 3,515 patients with immediate post-procedural hemodynamic data, of whom 224 were on hemodialysis (HD). Over a median follow-up of 434 days, all-cause mortality reached 33.0% in the HD cohort versus 16.7% in non-HD patients. Among non-HD patients, a post-procedural transmitral pressure gradient (TMPG) of ≥5 mmHg independently predicted mortality (adjusted HR 1.55; 95% CI 1.18–2.03), as did residual mitral regurgitation ≥2+ (adjusted HR 1.26; 95% CI 1.01–1.58). In the HD group, these associations were directionally similar but did not reach statistical significance, likely reflecting smaller subgroup size and competing mortality from non-cardiovascular causes — which accounted for 17.9% of HD deaths versus 6.6% in non-HD patients.
This finding sits within a growing body of evidence that dialysis-dependent patients face a qualitatively different disease trajectory after structural heart interventions. The systemic inflammatory burden, accelerated vascular calcification, and fluid-volume volatility intrinsic to end-stage renal disease likely overwhelm whatever marginal cardiovascular benefit a technically optimized TEER procedure might deliver. The study is observational and the HD subgroup is relatively small, limiting definitive causal conclusions. Still, the finding is clinically meaningful: traditional hemodynamic success metrics may be insufficient surrogates for survival in this population, suggesting the field needs HD-specific prognostic frameworks and potentially different patient selection criteria. Incremental rather than paradigm-shifting, but a necessary recalibration for an underserved high-risk group.